Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANSEP: Cannabinoids for Spasticity in Multiple Sclerosis
NCT05092191Phase 2Recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Nov 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dronabinol, cannabidiol in multiple sclerosis (MS), sponsored by Centre hospitalier de l’Université de Montréal. Started Nov 2022; status: recruiting.
02
Drugs
dronabinolcannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05092191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092191.